Developmental outcomes of 3,4-methylenedioxymethamphetamine (ecstasy)-exposed infants in the UK

Hum Psychopharmacol. 2015 Jul;30(4):290-4. doi: 10.1002/hup.2459.

Abstract

Objective: This paper aims to review findings from a longitudinal study of prenatal methylenedioxymethamphetamine (MDMA, "ecstasy") on infant development.

Methods: In a prospective, longitudinal cohort design, we followed 28 MDMA-exposed and 68 non-MDMA-exposed infants from birth to 2 years of age. Women recruited voluntarily into a study of recreational drug use during pregnancy were interviewed to obtain type, frequency, and amount of recreational drug use. Their children were followed for a 2-year period after birth. A large number of drug and environmental covariates were controlled. Infants were seen at 1, 4, 12, 18, and 24 months using standardized normative tests of mental and motor development.

Results: There were no differences between MDMA-exposed and non-MDMA-exposed infants at birth except that MDMA-exposed infants were more likely to be male. Motor delays were evident in MDMA infants at each age and amount of MDMA exposure predicted motor deficits at 12 months in a dose-dependent fashion.

Conclusions: Prenatal MDMA exposure is related to fine and gross motor delays in the first 2 years of life. Follow-up studies are needed to determine long-term effects.

Keywords: MDMA; ecstasy; infant development; methylenedioxymethamphetamine; motor; prenatal.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Age Factors
  • Child Development / drug effects*
  • Developmental Disabilities / etiology*
  • Female
  • Hallucinogens / adverse effects*
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • N-Methyl-3,4-methylenedioxyamphetamine / adverse effects*
  • Pregnancy
  • Prenatal Exposure Delayed Effects / chemically induced*
  • Prenatal Exposure Delayed Effects / physiopathology*
  • United Kingdom

Substances

  • Hallucinogens
  • N-Methyl-3,4-methylenedioxyamphetamine